Nova Minerals Corp (NYSE American / ASX: NVA) is back in a forensic fight. Spruce Point Capital (@sprucepointcap) says a new 10-K/A shows the largest insider and Director of Finance cut a large stake just as Alaska antimony permits arrived. A critic says the short seller compared CDIs with common shares. We lay out both claims, the permit catalyst and Spruce Point's longer short campaign.
This is journalism and commentary, not investment advice. We hold no position unless stated.
Key facts
- Ticker and exchange: Nova Minerals Corp, NVA, NYSE American (also ASX: NVA).
- Situation type: Activist forensic short versus a junior antimony and gold developer.
- The call: Spruce Point is short NVA; on October 29, 2026 it highlighted what it reads as a large insider reduction in a 10-K/A.
- Price: NVA closed at $3.45 on October 28, 2026 (last close before that post) and about $4.52 on November 5, 2026.
- Permit news: On October 27, 2026 Nova said it secured final permits for its Alaska antimony project, clearing a path toward 2027 production (company GlobeNewswire release).
- Token buys Spruce notes: Recent open-market purchases by directors and the CEO (Form 4s in mid/late October) were small relative to the alleged cut.
- Debate: StockSoftEng says 3,616,669 CDIs versus 436,806 common shares (including options) are different units at 12 CDIs per share, so there was "No sale."
Did the largest insider really sell?
Spruce Point's October 29 post applauds small director buys, then says the 10-K/A shows the largest insider and Director of Finance "appears to have sold a substantial position," "down from 2.26M to 0.43M" since end-September 2026 and "well below the 4.3M shares he owned in Sept '25," timed after permit news. It also notes the new CFO owns no stock.
On October 31, StockSoftEng replied: "3,616,669 is CDIs; the 10-K/A's 436,806 is common shares incl. 135,416 options. At 12 CDIs per share, 301,390 x 12 = 3,616,680. No sale." Spruce Point thanked the critic for clarifying in a short reply. Readers should compare the 10-K/A beneficial-ownership footnotes with ASX CDI disclosures rather than treat either tweet as final.
What else is on the table?
Spruce Point launched a detailed short report on February 20, 2026 titled around a "critical evaluation," estimating material downside and questioning infrastructure, weather, community pushback and commercial timelines. Nova published an ASX/SEC response arguing many points were historical or irrelevant and highlighting a U.S. Department of War award of about $43.4 million for domestic antimony. The October 27 permit release is the latest company catalyst shorts must underwrite.
Public Form 4 summaries for late October show small open-market buys by CEO Christopher Gerteisen and directors, not large sales - which is consistent with Spruce Point calling those buys "token" while still alleging a larger beneficial-ownership drop in the amended annual report.
Who's making this call and why?
Spruce Point Capital, founded by Ben Axler, specializes in forensic short-selling. On our scoreboard it is 11-6 (.647) on 17 scored career calls, average edge about +10.4 points, with shorts 11-6 and last 10 at 6-4. Rank 3 in the career long-term view we publish.
The October 29 note is a position update inside an open short, not a new initiation. Earlier October posts from the firm also pressed IperionX and Bunge; those tickers were already featured separately and are not re-featured here.
Other voices: Critical-minerals traders still list NVA among antimony names to watch. That is momentum color, not a scored forensic rebuttal. StockSoftEng's unit critique is the clearest public pushback on the specific 10-K/A claim.
Who disagrees?
- StockSoftEng: unit mismatch (CDI vs common) explains the headline drop; "No sale."
- Nova Minerals: February response to the original short report; October permit and production-path messaging.
- Form 4 tape: recent disclosed trades are small buys, which bulls read as confidence and Spruce Point reads as optics.
What are the key facts to verify?
- Beneficial ownership tables in the latest 10-K/A versus ASX CDI registers for the same person.
- Whether any Form 4 sale matches the alleged cut.
- Status of Alaska permits, DoW funding conditions and 2027 production milestones.
- Cash runway versus Spruce Point's claim the company has been running hot on cash.
What would prove it right or wrong?
Signals the short is working:
- Confirmed open-market insider selling, funding stress, or permit/DoW setbacks.
- Continued restatements or disclosure corrections that validate forensic claims.
Signals it is failing:
- Clean reconciliation showing no economic sale, plus funded progress to 2027 production.
- Sustained insider buying that is large relative to float, not token.
This is journalism and commentary, not investment advice. We hold no position unless stated.
